There is evidence that miR-223-3p might promote BC metastasis by regulating the lipid metabolism, which dysregulation is linked to tumour progression, by directly targeting SCARB1 (thus, suppressing cholesterol intake) and HMGCS1 (thus, suppressing cholesterol biosynthesis) [46]. This evidence concerns the gene HMGCS1 and breast cancer.